# Telatinib in Combination With Capecitabine/ Oxaliplatin in 1st Line Gastric or GEJ Cancer

> **NCT03817411** · PHASE2 · UNKNOWN · sponsor: **Taizhou EOC Pharma Co., Ltd.** · enrollment: 90 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Telatinib
- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT03817411
- **Lead sponsor:** Taizhou EOC Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-01-25
- **Primary completion:** 2020-03-30
- **Final completion:** 2021-01-25
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2019-05-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03817411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03817411, "Telatinib in Combination With Capecitabine/ Oxaliplatin in 1st Line Gastric or GEJ Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03817411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*